The Future of Targeted Alpha Therapy - Neal Shore
December 10, 2017
Dr. Neal Shore discusses the evolving interest in Alpha-Emitting Radionuclide Therapy over the past 20 years, which is due to advances in the targeted delivery of radionuclides as well as increased availability of many different alpha emitters. These developments have led to a number of clinical trials in this space, particularly with Radium-223, which is the only targeted alpha-emitter therapy currently approved for use on mCRPC patients.
There is no evidence that a resistance mechanism can develop to a targeted alpha therapy (TAT), so Dr. Shore addresses ways to link payloads of other diagnostic entities to TAT. He also explores TAT’s biological consequences, what we’ve learned from radium-223, the first-in class TAT, and combining TAT with immunotherapy treatment, DNA repair inhibitors and hormonal therapy to enhance therapeutic benefit for the patient.
Related Clinical Trials on Targeted Alpha Therapy:
A Randomized, Phase II Study Evaluating the Addition of Pembrolizumab (MK-3475) to Radium-223 in Metastatic Castration Resistant Prostate Cancer (mCRPC)
A Phase Ib, Open-Label Study of the Safety and Tolerability of Atezolizumab in Combination With Radium-223 Dichloride in Patients With Castrate-Resistant Prostate Cancer Who Have Progressed Following Treatment With an Androgen Pathway Inhibitor
A Phase 2 Study of Sipuleucel-T With or Without Radium-223 in Men With Asymptomatic or Minimally Symptomatic Bone-Metastatic Castrate-Resistant Prostate Cancer
A Randomized Multicenter Phase III Trial Comparing Enzalutamide vs. a Combination of Ra223 and Enzalutamide in Asymptomatic or Mildly Symptomatic Castration Resistant Prostate Cancer Patients Metastatic to Bone.
Phase IB Trial of Radium-223 and Niraparib in Patients With Castrate Resistant Prostate Cancer (NiraRad)
Related Content on Targeted Alpha Therapy:
ESMO 2017: Panel Discussion – Targeted Alpha Therapy
A Review On The Development of Targeted Alpha Therapy in the Treatment of Cancer: EVERYDAY UROLOGY-Full Text Article
10th International Symposium on Targeted Alpha Therapy (TAT-10) May 31 - June 1, 2017
Neal Shore, MD, FACS